Status:
COMPLETED
A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes
Lead Sponsor:
Mayo Clinic
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
3-18 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine if children with type 1 diabetes have adequate immune response to PPSV23 vaccination and to assess factors affecting immune response.
Eligibility Criteria
Inclusion
- Children ages 3-18 years old.
- Clinical diagnosis of Type 1 diabetes.
Exclusion
- Newly diagnosed with Type 1 diabetes with in the past month of study date.
- Contraindications to receiving 23 valent pneumococcal vaccines.
- Other conditions associated with compromised immunity and vaccine response.
- Primary or Secondary Immune deficiency.
- Previous receipt of PPSV-23 vaccination.
Key Trial Info
Start Date :
April 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2023
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04481243
Start Date
April 30 2021
End Date
January 20 2023
Last Update
November 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905